EUCTR2004-000422-73-IT进行中（未招募）不适用
OPEN-LABEL, CONTROLLED, RANDOMISED, MULTICENTRE, PARALLEL GROUP CLINICAL TRIAL OF EFFICACY AND TOLERABILITY OF FITOSTIMOLINE ANTIBIOTICO SOAKED GAUZES AND CITRIZAN GEL ANTIBIOTIC IN THE TOPICAL TREATMENT OF CUTANEOUS SORES, ULCERS AND BURNS, COMPLICATED WITH BACTERIAL CONTAMINATION the so-called infected lesions
FARMACEUTICI DAMOR0 个研究点目标入组 160 人开始时间: 2006年12月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
on-blinded phase II study to compare the efficacy and safety of CetuGEX™ plus chemotherapy with cetuximab plus chemotherapy for the treatment of patients with stage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neckstage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neckMedDRA version: 14.1Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003695-13-ITGlycotope GmbH240
进行中（未招募）
1 期
on-blinded phase II study to compare the efficacy and safety of CetuGEX? plus chemotherapy with cetuximab plus chemotherapy for the treatment of patients with stage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neckstage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neckMedDRA version: 14.1Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003695-13-ESGlycotope GmbH240
进行中（未招募）
1 期
on-blinded phase II study to compare the efficacy and safety of CetuGEX™ plus chemotherapy with cetuximab plus chemotherapy for the treatment of patients with stage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neckEUCTR2013-003695-13-PLGlycotope GmbH240
进行中（未招募）
1 期
on-blinded phase II study to compare the efficacy and safety of CetuGEX™ plus chemotherapy with cetuximab plus chemotherapy for the treatment of patients with stage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neckstage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neckMedDRA version: 20.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003695-13-DEGlycotope GmbH240
进行中（未招募）
1 期
on-blinded phase II study to compare the efficacy and safety of CetuGEX™ plus chemotherapy with cetuximab plus chemotherapy for the treatment of patients with stage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neckEUCTR2013-003695-13-BEGlycotope GmbH240